Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt No Debt
IMUC's Cash-to-Debt is ranked higher than
86% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. IMUC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
IMUC' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -10.81
Beneish M-Score: 2.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -162.65
IMUC's ROE % is ranked lower than
87% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. IMUC: -162.65 )
Ranked among companies with meaningful ROE % only.
IMUC' s ROE % Range Over the Past 10 Years
Min: -480.22  Med: -120.17 Max: -35.53
Current: -162.65
-480.22
-35.53
ROA % -97.59
IMUC's ROA % is ranked lower than
83% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. IMUC: -97.59 )
Ranked among companies with meaningful ROA % only.
IMUC' s ROA % Range Over the Past 10 Years
Min: -179.88  Med: -88.12 Max: -31.45
Current: -97.59
-179.88
-31.45
ROC (Joel Greenblatt) % -6860.96
IMUC's ROC (Joel Greenblatt) % is ranked lower than
83% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. IMUC: -6860.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IMUC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -79400  Med: -16598.23 Max: 13323.94
Current: -6860.96
-79400
13323.94
3-Year EPS without NRI Growth Rate 7.20
IMUC's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. IMUC: 7.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IMUC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -28.1  Med: -4.4 Max: 81.7
Current: 7.2
-28.1
81.7
GuruFocus has detected 2 Warning Signs with ImmunoCellular Therapeutics Ltd $IMUC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IMUC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

IMUC Guru Trades in

IMUC Guru Trades in

IMUC Guru Trades in

Q4 2016

IMUC Guru Trades in Q4 2016

Jim Simons 97,604 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with IMUC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:NAS:CLSN, OTCPK:PTIX, OTCPK:BITRF, OTCPK:VDQSF, OTCPK:STLT, AMEX:APHB, NAS:CERC, OTCPK:AYTU, OTCPK:PVOTF, OTCPK:CRYO, OTCPK:CDXI, OTCPK:PPCH, OTCPK:REPCF, OTCBB:RGBP, OTCPK:SARSF, OTCPK:VRTHF, NAS:RXII, OTCPK:WLDFF, OTCPK:LIXT, OTCPK:NMUS » details
Traded in other countries:KOL1.Germany,
ImmunoCellular Therapeutics Ltd is a clinical-stage biotechnology company that develops immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.

ImmunoCellular Therapeutics Ltd was incorporated with the Secretary of State of Delaware on March 20, 1987 under the name Redwing Capital Corp. On November 2, 2006, it amended its Certificate of InCorporation to change its name to ImmunoCellular Therapeutics, Ltd. The Company is a clinical-stage biotechnology company developing immune-based therapies for the treatment of cancers, such as brain and ovarian. Immunotherapy is an approach to treating cancer in which a patient's own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company's product candidate portfolio includes; ICT-107, ICT-121, and ICT-140. The ICT-107 is a DC-based vaccine targeting CSCs and cancer antigens that targets six different tumor-associated antigens that are found on patients' tumor cells; at least four of the six antigens are highly expressed on CSCs. The therapeutic vaccine is used subsequent to conventional therapy or concomitantly with chemotherapy in patients with newly diagnosed GBM. On February 2014, ICT-107 was granted Orphan Drug status by the European Medicines Agency. The ICT-121 is a DC-based vaccine targeting CD133+ CSCs marker that is overexpressed in a wide variety of solid tumors, including ovarian, pancreatic, and breast cancers. The ICT-140 is a DC-based vaccine targeting CSCs and cancer antigens and targets seven different ovarian cancer antigens. Ovarian cancer usually spreads via local shedding into the peritoneal cavity followed by implantation on the peritoneum and via local invasion of bowel and bladder. The Company faces competition from the companies that have significantly more experience in undertaking preclinical testing and human clinical trials with new or improved therapeutic products and obtaining regulatory approvals of such products. The United States and other developed countries regulate the preclinical and clinical testing, manufacturing, labeling, storage, record-keeping, advertising, promotion, export, marketing and distribution of drugs and biologic products. The United States Food and Drug Administration, under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal statutes and regulations, regulate pharmaceutical and biologic products.

Ratios

vs
industry
vs
history
PB Ratio 1.52
IMUC's PB Ratio is ranked higher than
83% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. IMUC: 1.52 )
Ranked among companies with meaningful PB Ratio only.
IMUC' s PB Ratio Range Over the Past 10 Years
Min: 0.23  Med: 6 Max: 18.01
Current: 1.52
0.23
18.01
EV-to-EBIT 0.11
IMUC's EV-to-EBIT is ranked higher than
97% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. IMUC: 0.11 )
Ranked among companies with meaningful EV-to-EBIT only.
IMUC' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.9  Med: -4.7 Max: 2
Current: 0.11
-19.9
2
EV-to-EBITDA 0.11
IMUC's EV-to-EBITDA is ranked higher than
97% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. IMUC: 0.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
IMUC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.9  Med: -4.7 Max: 2
Current: 0.11
-19.9
2
Current Ratio 4.14
IMUC's Current Ratio is ranked higher than
52% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. IMUC: 4.14 )
Ranked among companies with meaningful Current Ratio only.
IMUC' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 11.39 Max: 69.45
Current: 4.14
0.98
69.45
Quick Ratio 3.78
IMUC's Quick Ratio is ranked higher than
50% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. IMUC: 3.78 )
Ranked among companies with meaningful Quick Ratio only.
IMUC' s Quick Ratio Range Over the Past 10 Years
Min: 0.98  Med: 11.18 Max: 69.45
Current: 3.78
0.98
69.45

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -33.70
IMUC's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. IMUC: -33.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IMUC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -51.6  Med: -30.2 Max: -19.3
Current: -33.7
-51.6
-19.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 13.45
IMUC's Price-to-Net-Cash is ranked lower than
73% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. IMUC: 13.45 )
Ranked among companies with meaningful Price-to-Net-Cash only.
IMUC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.02  Med: 4.45 Max: 74.22
Current: 13.45
1.02
74.22
Price-to-Net-Current-Asset-Value 3.49
IMUC's Price-to-Net-Current-Asset-Value is ranked higher than
70% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. IMUC: 3.49 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
IMUC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.01  Med: 2.66 Max: 70.8
Current: 3.49
1.01
70.8
Price-to-Tangible-Book 1.51
IMUC's Price-to-Tangible-Book is ranked higher than
87% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. IMUC: 1.51 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IMUC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1  Med: 2.01 Max: 70.64
Current: 1.51
1
70.64
Earnings Yield (Greenblatt) % 972.79
IMUC's Earnings Yield (Greenblatt) % is ranked higher than
99% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. IMUC: 972.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IMUC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 49.5  Med: 88.9 Max: 3471
Current: 972.79
49.5
3471

More Statistics

EPS (TTM) $ -8.24
Beta0.63
Short Percentage of Float9.62%
52-Week Range $1.83 - 13.60
Shares Outstanding (Mil)3.44

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -8.57
EPS without NRI ($) -8.57
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for IMUC

Headlines

Articles On GuruFocus.com

More From Other Websites
6:01 am ImmunoCellular Therapeutics and Memgen sign a non-binding LOI to exclusively negotiate the... Mar 23 2017
ImmunoCellular Therapeutics and Memgen Announce Letter of Intent for Potential Joint Immuno-Oncology... Mar 23 2017
IMMUNOCELLULAR THERAPEUTICS, LTD. Financials Mar 15 2017
ImmunoCellular Therapeutics Receives Audit Opinion With Going Concern Explanation Mar 14 2017
Edited Transcript of IMUC earnings conference call or presentation 9-Mar-17 10:00pm GMT Mar 10 2017
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 09 2017
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and... Mar 09 2017
Q4 2016 ImmunoCellular Therapeutics Ltd Earnings Release - After Market Close Mar 09 2017
ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on March... Mar 06 2017
ImmunoCellular Therapeutics Provides Update on ICT-107 Phase 3 Glioblastoma Trial and Announces... Mar 06 2017
Latest Reports on ImmunoCellular Therapeutics and Neuralstem as Biotech Industry Scrutiny Grows... Jan 12 2017
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Change in Directors or Principal Officers,... Dec 14 2016
ImmunoCellular Therapeutics Announces Management Changes Dec 14 2016
ImmunoCellular Therapeutics Reports Updated Immune Monitoring Data from ICT-107 Phase 2 Trial in... Nov 21 2016
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws;... Nov 18 2016
ImmunoCellular Therapeutics Announces One-for-Forty Reverse Stock Split Nov 16 2016
ImmunoCellular Therapeutics Announces One-for-Forty Reverse Stock Split Nov 16 2016
Edited Transcript of IMUC earnings conference call or presentation 10-Nov-16 10:00pm GMT Nov 14 2016
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 10 2016
ImmunoCellular Therapeutics Announces Third Quarter 2016 Financial Results and Provides Research and... Nov 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)